Hypertension Diagnostics Stock Current Liabilities
HDIIDelisted Stock | USD 0 0.0008 38.10% |
Hypertension Diagnostics fundamentals help investors to digest information that contributes to Hypertension Diagnostics' financial success or failures. It also enables traders to predict the movement of Hypertension Pink Sheet. The fundamental analysis module provides a way to measure Hypertension Diagnostics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Hypertension Diagnostics pink sheet.
Hypertension |
Hypertension Diagnostics Company Current Liabilities Analysis
Hypertension Diagnostics' Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current Hypertension Diagnostics Current Liabilities | 1.13 M |
Most of Hypertension Diagnostics' fundamental indicators, such as Current Liabilities, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Hypertension Diagnostics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
CompetitionIn accordance with the recently published financial statements, Hypertension Diagnostics has a Current Liabilities of 1.13 M. This is 99.96% lower than that of the Health Care Equipment & Supplies sector and significantly higher than that of the Health Care industry. The current liabilities for all United States stocks is 99.99% higher than that of the company.
Hypertension Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Hypertension Diagnostics' direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Hypertension Diagnostics could also be used in its relative valuation, which is a method of valuing Hypertension Diagnostics by comparing valuation metrics of similar companies.Hypertension Diagnostics is currently under evaluation in current liabilities category among its peers.
Hypertension Fundamentals
Return On Asset | 3.0E-4 | ||||
Profit Margin | (0.03) % | ||||
Operating Margin | 0.0002 % | ||||
Current Valuation | 5.26 M | ||||
Shares Outstanding | 52.39 M | ||||
Price To Earning | (0.03) X | ||||
Price To Sales | 0.15 X | ||||
Revenue | 3.79 M | ||||
Gross Profit | 954.47 K | ||||
EBITDA | 72.29 K | ||||
Net Income | (125.39 K) | ||||
Cash And Equivalents | 5.66 K | ||||
Total Debt | 4.69 M | ||||
Current Ratio | 0.52 X | ||||
Book Value Per Share | (0.09) X | ||||
Cash Flow From Operations | (389.28 K) | ||||
Earnings Per Share | (0) X | ||||
Beta | -0.92 | ||||
Market Capitalization | 730.42 K | ||||
Total Asset | 1.28 M | ||||
Retained Earnings | (30.68 M) | ||||
Working Capital | (857 K) | ||||
Current Asset | 277 K | ||||
Current Liabilities | 1.13 M | ||||
Z Score | -31.6 | ||||
Net Asset | 1.28 M |
About Hypertension Diagnostics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Hypertension Diagnostics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Hypertension Diagnostics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Hypertension Diagnostics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Other Consideration for investing in Hypertension Pink Sheet
If you are still planning to invest in Hypertension Diagnostics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Hypertension Diagnostics' history and understand the potential risks before investing.
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
CEOs Directory Screen CEOs from public companies around the world | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |